SEROPHENE Drug Patent Profile

« Back to Dashboard

Which patents cover Serophene, and what generic alternatives are available?

Serophene is a drug marketed by Emd Serono and is included in one NDA.

The generic ingredient in SEROPHENE is clomiphene citrate. There is one drug master file entry for this compound. Eleven suppliers are listed for this compound. Additional details are available on the clomiphene citrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Serophene

A generic version of SEROPHENE was approved as clomiphene citrate by APPCO on November 8^th, 2024.

Summary for SEROPHENE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	110
Clinical Trials:	6
Patent Applications:	2,348
DailyMed Link:	SEROPHENE at DailyMed

Recent Clinical Trials for SEROPHENE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yale University	Phase 1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1
University of Illinois at Chicago	Phase 1

See all SEROPHENE clinical trials

US Patents and Regulatory Information for SEROPHENE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Emd Serono	SEROPHENE	clomiphene citrate	TABLET;ORAL	018361-001	Mar 22, 1982		DISCN	No	No

Serophene Market Dynamics, Patent Status, and Financial Trajectory

Last updated: September 30, 2026

Serophene is a brand of clomiphene citrate, a generic oral ovulation-induction drug used primarily in infertility treatment. Its commercial value is now concentrated in the active ingredient and generic market rather than the Serophene brand. U.S. composition, formulation, and regulatory exclusivities expired decades ago. Generic clomiphene competes mainly on price, availability, pharmacy contracting, and fertility-clinic relationships.

No standalone Serophene revenue is publicly reported by the brand owner. The commercial trajectory is therefore best assessed through the clomiphene citrate market, prescription volumes, generic pricing, infertility-treatment demand, and the decline of branded pharmaceutical economics.

What is Serophene and how is it used?

Serophene contains clomiphene citrate, a selective estrogen receptor modulator that induces ovulation in women with ovulatory dysfunction. It is administered orally, typically in 50-mg tablets, under a short-course treatment regimen. The FDA-approved label covers ovulatory failure in patients seeking pregnancy after appropriate diagnostic evaluation.[1]

Clomiphene is also used off label in male reproductive medicine, particularly for secondary hypogonadism and fertility preservation. That use is commercially relevant because prescriptions may be generated outside the drug's original female infertility indication, although the FDA has not approved clomiphene for male hypogonadism.

Serophene product profile

Attribute	Serophene position
Active ingredient	Clomiphene citrate
Drug class	Selective estrogen receptor modulator
Primary indication	Ovulation induction
Dosage form	Oral tablet
Common strength	50 mg
FDA status	Approved active ingredient; Serophene brand availability is limited or discontinued in the U.S.
Regulatory pathway	Original NDA followed by ANDA generic competition
Biologic status	Not a biologic
Biosimilar exposure	None
Current commercial model	Generic clomiphene citrate, fertility-clinic use, and international branded products

Clomiphene is generally used before or alongside other fertility interventions, including timed intercourse, intrauterine insemination, and assisted reproductive technology. Letrozole has become a major competing ovulation-induction therapy, particularly for polycystic ovary syndrome.

What is the FDA and Orange Book status of Serophene?

The relevant FDA commercial status is the status of clomiphene citrate, not a current branded Serophene franchise. FDA labeling records show that clomiphene citrate received approval for ovulatory dysfunction and that generic products are available through abbreviated new drug applications.[1][2]

Serophene does not have a commercially meaningful period of remaining FDA exclusivity. The original regulatory exclusivity period ended long ago, and generic manufacturers can rely on the established safety and efficacy record through the ANDA pathway.

Orange Book and regulatory position

Regulatory issue	Assessment
Current new-drug exclusivity	None identified
Unexpired U.S. compound patent	None relevant to current clomiphene access
Unexpired formulation patent	None known to block standard generic tablets
Pediatric exclusivity	None relevant
Orphan exclusivity	None
ANDA competition	Established
Therapeutic-equivalence framework	Applicable to approved generic tablets
Paragraph IV risk	Low for the legacy product because core exclusivity expired decades ago

The Orange Book is important for identifying listed patents and therapeutic-equivalence ratings. For an old small-molecule product such as clomiphene, the primary commercial question is not patent litigation but whether manufacturers maintain approved supply and acceptable margins.[2]

When did Serophene lose exclusivity?

Serophene lost meaningful exclusivity many years ago. Clomiphene citrate was introduced in the 1960s, and the active ingredient has been available in generic form for decades. Any original compound, use, or formulation protections would have expired no later than the early 2000s, assuming conventional U.S. patent terms and the absence of unusually extended rights.

The commercial exclusivity timeline is therefore:

Period	Event	Market effect
1960s	FDA approval of clomiphene citrate	Original branded market established
1970s-1980s	Branded infertility treatment expands	Brand pricing and physician familiarity increase
1980s-1990s	Generic availability develops	Price competition begins
1990s-2000s	Core patent and exclusivity rights expire	Brand monopoly ends
2000s-present	Generic clomiphene becomes the principal U.S. supply	Low-cost, multisupplier market
Present	Brand Serophene has limited U.S. commercial relevance	Market value resides in generic demand

No current patent should prevent an FDA-approved generic manufacturer from marketing conventional clomiphene citrate tablets in the United States.

What patents protect Serophene and clomiphene citrate?

No active U.S. patent estate is known to protect the core Serophene product. The relevant legacy rights would have covered the clomiphene compound, pharmaceutical compositions, manufacturing processes, or ovulation-induction use. Those rights are no longer a meaningful barrier to generic entry.

Patent categories relevant to clomiphene

Patent category	Current commercial significance
Composition of matter	Expired
Basic pharmaceutical formulation	Expired or no longer exclusionary
Ovulation-induction method	Expired for the original approved use
Tablet manufacturing process	Not a practical barrier where alternative processes are available
New dosage regimen	Potentially patentable in principle, but not a current Serophene barrier
Enantiomer or stereoisomer claims	May support separate products in theory, but do not protect conventional clomiphene citrate
Packaging or labeling claims	Limited value and generally avoidable by generics

Clomiphene citrate has stereochemical complexity, but the historical product and generic market are based on the established citrate drug substance. A new formulation or combination product could pursue separate patent protection, but that would not restore exclusivity to legacy Serophene.

How strong is the Serophene patent estate?

The Serophene patent estate is commercially weak because it no longer restricts generic supply. Patent strength should be assessed across four dimensions:

Dimension	Current assessment
Remaining patent life	None of material commercial relevance
Claim breadth	Legacy claims covered an established generic molecule
Design-around risk	Not relevant because generic manufacturers already compete
Litigation leverage	Minimal
Regulatory leverage	Minimal
Licensing value	Low for the legacy brand

The absence of meaningful patent protection shifts competitive advantage to manufacturing economics, distribution, regulatory compliance, and demand generation. A company acquiring Serophene would be acquiring a legacy brand or trademark, not a protected pharmaceutical platform.

Which companies compete with Serophene?

The principal competitors are generic clomiphene manufacturers and alternative fertility drugs. The market is fragmented and includes manufacturers that supply pharmacies, wholesalers, fertility clinics, and international distributors.

Direct competitors

Direct competitors sell clomiphene citrate tablets under generic labels or regional brands. Competition depends on:

• FDA approval and therapeutic equivalence
• Active pharmaceutical ingredient sourcing
• Reliable tablet production
• Wholesale acquisition cost
• Pharmacy benefit coverage
• Back-order performance
• Ability to meet controlled-quality and pharmacovigilance requirements

The branded Clomid product historically competed directly with Serophene. In the current U.S. market, both branded products have far less commercial influence than generic clomiphene.

Therapeutic competitors

Letrozole is the most important therapeutic competitor. It is an aromatase inhibitor used off label for ovulation induction and is widely used in patients with polycystic ovary syndrome. A randomized trial published in the New England Journal of Medicine found higher live-birth and ovulation outcomes with letrozole than with clomiphene in women with polycystic ovary syndrome.[3]

Gonadotropins, metformin in selected patients, and assisted reproductive technologies also compete for fertility-treatment spending. These alternatives can increase total treatment cost while reducing the number of cycles using clomiphene.

How does Serophene compare with letrozole?

Factor	Clomiphene citrate	Letrozole
Primary use in fertility	Ovulation induction	Ovulation induction, especially PCOS
FDA fertility indication	Yes, for ovulatory failure	Not specifically approved for ovulation induction
Typical market position	Established, low-cost generic	Increasing first-line use in PCOS
Generic status	Mature generic market	Mature generic market
Mechanism	Selective estrogen receptor modulation	Aromatase inhibition
Key commercial advantage	Long clinical history and low price	Strong clinical adoption in PCOS
Main limitation	Anti-estrogenic effects and reduced endometrial benefit in some patients	Off-label fertility use in the U.S.
Patent exposure	None material	None material for conventional generic letrozole

Clinical practice changes, not patent barriers, are the main source of demand risk for clomiphene. If fertility specialists continue shifting toward letrozole, clomiphene volumes may decline even while the total infertility-treatment market expands.

What is the financial trajectory for Serophene?

Serophene's financial trajectory is a mature-product decline, not a growth-brand trajectory. Standalone brand revenue is not publicly disclosed, and the product does not appear to be a separately reported revenue segment for a major public pharmaceutical company.

The economic profile has four phases:

Brand expansion

During the branded period, Serophene benefited from physician familiarity, the absence of generic substitution, and the growth of infertility diagnosis and treatment. Revenue depended on prescription volume multiplied by branded pricing.

Generic erosion

Once generic clomiphene became available, substitution reduced brand volume and forced price competition. The brand lost the ability to support premium pricing without differentiated packaging, supply reliability, or physician loyalty.

Mature generic market

The current market is driven by relatively stable clinical demand and low per-tablet pricing. Generic manufacturers can earn revenue through volume, but gross margins are exposed to:

• Active ingredient costs
• Contract manufacturing
• Quality-control expenses
• FDA compliance
• Wholesaler discounts
• Pharmacy purchasing power
• Periodic supply shortages
• Small market size relative to large generic products

Long-term demand pressure

Long-term demand is exposed to treatment substitution. Letrozole has gained clinical acceptance, and some patients proceed directly to intrauterine insemination or in vitro fertilization. At the same time, delayed childbearing, infertility diagnosis, and growing access to reproductive care support baseline demand for oral ovulation-induction medicines.

Financial outlook

Metric	Outlook
Branded Serophene revenue	Limited and difficult to isolate
Generic clomiphene volume	Stable to declining in mature markets
Average selling price	Low, with periodic supply-driven volatility
Gross-margin potential	Moderate to low
Market-entry barriers	Regulatory and manufacturing, not patent-based
Revenue concentration	Distributed among generic manufacturers
Growth driver	Infertility-treatment volume
Revenue risk	Substitution by letrozole and assisted reproduction
M&A value	Primarily brand, distribution, or regional rights

What generic entry risks exist for Serophene?

Generic entry risk is no longer a future event. It is the defining structure of the market. Any company commercializing Serophene faces permanent generic substitution unless it operates in a jurisdiction where the brand retains unusual market recognition or reimbursement advantages.

A generic manufacturer considering entry would face less patent risk than execution risk. The principal barriers are:

1. FDA approval and bioequivalence requirements.
2. Consistent sourcing of clomiphene citrate.
3. Manufacturing capacity for low-volume oral solid doses.
4. Quality-system compliance.
5. Distribution economics.
6. Pharmacy substitution and reimbursement pressure.
7. Product liability and pharmacovigilance obligations.

A new entrant could launch under an ANDA without negotiating a patent settlement if no blocking listed patent remains. Paragraph IV litigation is therefore not a central risk for conventional clomiphene tablets.

What formulation patents protect clomiphene products?

Standard Serophene and generic clomiphene tablets do not have a commercially important formulation patent moat. A company could seek patents for a novel delivery system, modified-release formulation, combination product, or improved tolerability profile. Such claims would need to demonstrate patentable technical differences and satisfy FDA requirements for the proposed product.

Potentially differentiating concepts include:

• Modified-release clomiphene
• Lower-dose formulations
• Combination therapy with another fertility medicine
• Improved tablet stability
• Patient-specific dosing systems
• Novel delivery routes

These concepts would create new regulatory and clinical-development costs. They would not extend protection for conventional Serophene tablets.

Is Serophene affected by biosimilar competition?

No. Serophene is a small-molecule drug, not a biologic. Biosimilar competition under the Public Health Service Act does not apply. Competition occurs through the generic-drug pathway under the Federal Food, Drug, and Cosmetic Act, principally through ANDAs and therapeutic-equivalence determinations.[2][4]

This distinction matters commercially. Generic manufacturers generally face lower development costs and shorter clinical requirements than biosimilar developers. The result is a lower barrier to entry and greater price erosion for clomiphene.

What patent litigation or settlement agreements affect Serophene?

No current high-value patent litigation or settlement structure is central to the U.S. Serophene market. The drug's core exclusivity expired long ago, and generic availability is established.

The absence of active patent disputes means that commercial outcomes depend on ordinary generic-market variables rather than litigation timing. A future dispute could arise over a novel formulation, a new indication, or a manufacturing process, but such a dispute would concern the new product or process rather than legacy Serophene tablets.

What geographic markets still matter for Serophene?

The United States is commercially important because of its large fertility-treatment market and established generic distribution, but the brand's relevance varies by country. Serophene or equivalent clomiphene brands may retain stronger recognition in markets where generic substitution is weaker or where physicians prescribe by brand.

Geographic value depends on:

• National approval status
• Reimbursement policy
• Generic substitution rules
• Local infertility-treatment access
• Import and supply requirements
• Brand recognition among fertility specialists
• Availability of letrozole and gonadotropins

In emerging markets, clomiphene can remain commercially relevant because it is inexpensive, orally administered, and easier to distribute than injectable fertility products. However, local registration and pricing rules can limit margins.

What is the likely generic launch scenario?

A new generic entrant would most likely use the standard ANDA route, launch after confirming FDA approval and supply readiness, and compete through price and channel access. A Paragraph IV launch is unlikely to be necessary for the conventional product because no material blocking patent is expected.

Scenario analysis

Scenario	Market effect
Additional generic entrant	Lower prices and reduced incumbent volume
Manufacturer withdrawal	Temporary supply tightening and possible price increases
Letrozole adoption accelerates	Lower clomiphene prescription volume
Fertility-treatment demand expands	Supports stable unit demand
New formulation launches	Creates a separate, potentially protected niche
Brand relaunch	Limited pricing power without clinical differentiation

The most attractive opportunity is not a traditional Serophene relaunch. It is a differentiated fertility product with new clinical evidence, a new formulation, or an efficient regional distribution model.

Key Takeaways

• Serophene is a legacy clomiphene citrate brand used for ovulation induction.
• Its U.S. commercial value is limited because generic clomiphene has been available for decades.
• No material current patent, regulatory exclusivity, or Orange Book barrier protects conventional Serophene tablets.
• The product is not exposed to biosimilar competition because it is a small-molecule drug.
• Letrozole is the principal therapeutic competitor, especially in polycystic ovary syndrome.
• Standalone Serophene revenue is not publicly reported.
• The financial profile is mature and low-margin, with value concentrated in generic volume, supply reliability, and regional distribution.
• Future growth would require a differentiated formulation, combination product, new clinical positioning, or geographic expansion.
• Generic-entry risk is already realized rather than prospective.
• The main commercial threats are therapeutic substitution and low pricing, not patent litigation.

FAQs About Serophene Market Value and Exclusivity

Is Serophene still sold in the United States?

Serophene has limited U.S. commercial visibility, while generic clomiphene citrate remains available through approved generic products and pharmacy channels.

Does Serophene have an active patent?

No material active U.S. patent is known to protect conventional Serophene or generic clomiphene citrate tablets.

Is clomiphene more profitable than letrozole?

Neither drug generally has strong branded economics in the United States because both are mature small-molecule products with generic competition. Profitability depends on manufacturing cost, supply conditions, and distribution contracts.

Can a company relaunch Serophene as a premium fertility drug?

A relaunch could use brand recognition, but legacy Serophene alone does not support durable premium pricing. A premium strategy would require new clinical evidence, a differentiated formulation, or a protected combination product.

Does Serophene face FDA biosimilar competition?

No. Serophene is a small-molecule drug and competes through the generic-drug framework rather than the biosimilar pathway.

References

1. U.S. Food and Drug Administration. (2012). Clomid (clomiphene citrate) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. Legro, R. S., Brzyski, R. G., Diamond, M. P., Coutifaris, C., Schlaff, W. D., Casson, P., Christman, G. M., Huang, H., Yan, Q., Alvero, R., Haisenleder, D. J., Krawetz, S. A., Barnhart, K. T., Bates, G. W., Usadi, R., Lucidi, R. S., Baker, V. L., Ohl, D., Ford, P., ... Myers, E. (2014). Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. New England Journal of Medicine, 371(2), 119-129. https://doi.org/10.1056/NEJMoa1313517

4. U.S. Food and Drug Administration. (2024). Generic drug facts. FDA.